Krystal Biotech, Inc. KRYS

Krystal Biotech’s strongest sourced fact is the one a normal reader can hold without a spreadsheet: the company reported product revenue, net, of $116.4 million for the three months ended March 31, 2026, compared with $88.2 million for the same period in 2025, a $28.2 million increase and 32% growth on the official 10-Q rail.

The company story in this evidence pack runs through VYJUVEK. The 10-Q says net VYJUVEK product revenue was $116.4 million for the three months ended March 31, 2026, and that cumulative net product revenue since the first United States launch of VYJUVEK in 2023 reached $846.7 million. That makes the current file less about abstract biotech hope and more about a marketed product already shaping reported revenue.

The latest available SEC EDGAR filed financials show net income attributable to parent of $55.9 million, operating income of $53.7 million and diluted earnings per share of $1.83 for the period ending March 31, 2026. The same rail shows $501.3 million of cash and cash equivalents, $1.40 billion of assets, $120.2 million of liabilities, $1.28 billion of stockholders’ equity attributable to parent, $80.4 million of net cash provided by operating activities, $15.3 million of research and development expense, $42.6 million of inventory, a $243,000 increase in inventories, $7.1 million of payments to acquire property, plant and equipment, and diluted weighted average shares outstanding of 30.5 million.

The source route here is SEC heavy. The named public developments are recent EDGAR filings: two KRYS Form 4 filings dated June 5, 2026, two Form 144 filings dated June 4, 2026, a KRYS Form 4 dated May 27, 2026, a Form 144 dated May 26, 2026, the SEC filing index, the SEC submissions JSON, the SEC companyfacts JSON and the official 10-Q filed on May 4, 2026. The supplied rail does not include a chart route, trading levels, volume, analyst notes or price action, so the market mechanism has to be read through filings, reported product revenue, cash generation and public ownership disclosures rather than candle watching.

What changed on the supplied rail is filing activity after the 10-Q: Form 144 notices and Form 4 filings in late May and early June. Those filings are relevant because they are named public developments from SEC EDGAR, but the pack does not supply transaction amounts, prices, officer names or intent text, so the report cannot turn them into a motive story. The cleaner conclusion is narrower and stronger: the current evidence shows a profitable March quarter, a real VYJUVEK revenue base, substantial cash, modest liabilities relative to assets, and recent governance filings that deserve attention without overinterpretation.